New targeted drug shows promise for rare cancer mutation
Disease control
Ongoing
This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…
Phase: PHASE1 • Sponsor: Alterome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC